About The Study: In this randomized, placebo-controlled clinical trial that included 3,020 patients with high-risk nonmetastatic breast cancer, daily aspirin therapy did not improve risk of breast cancer recurrence or survival in early follow-up. Despite its promise and wide availability, aspirin should not be recommended as an adjuvant breast cancer treatment.
About The Study: In this randomized, placebo-controlled clinical trial that included 3,020 patients with high-risk nonmetastatic breast cancer, daily aspirin therapy did not improve risk of breast cancer recurrence or survival in early follow-up. Despite its promise and wide availability, aspirin should not be recommended as an adjuvant breast cancer treatment.
Authors: Wendy Y. Chen, M.D., of the Dana Farber Cancer Institute in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jama.2024.4840)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA
Cite Scienmag News
Nathaniel Bowman. (April 29, 2024). Aspirin vs placebo as adjuvant therapy for breast cancer. Scienmag. https://scienmag.com/aspirin-vs-placebo-as-adjuvant-therapy-for-breast-cancer/
Nathaniel Bowman. "Aspirin vs placebo as adjuvant therapy for breast cancer." Scienmag, 29 April 2024, https://scienmag.com/aspirin-vs-placebo-as-adjuvant-therapy-for-breast-cancer/. Accessed 3 September 2026.
Nathaniel Bowman. "Aspirin vs placebo as adjuvant therapy for breast cancer." Scienmag. April 29, 2024. https://scienmag.com/aspirin-vs-placebo-as-adjuvant-therapy-for-breast-cancer/
